Brean Murray Carret & Co. Starts Salix Pharmaceuticals (SLXP) at Buy; Going With Our Gut
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Price: $172.81 --0%
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Brean Murray Carret & Co. initiates coverage on Salix Pharmaceuticals (NASDAQ: SLXP) with a Buy. PT $50.
Brean analyst says, "Salix has over $430 million in cash, and we expect it to be cash flow positive, going forward. The key difference in our valuation is that we are more aggressive on Relistor's potential than our peers."
For more ratings news on Salix Pharmaceuticals click here and for the rating history of Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $38.34 yesterday.
Brean analyst says, "Salix has over $430 million in cash, and we expect it to be cash flow positive, going forward. The key difference in our valuation is that we are more aggressive on Relistor's potential than our peers."
For more ratings news on Salix Pharmaceuticals click here and for the rating history of Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $38.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts Aditya Birla Real Estate (ABREL:IN) at Buy
- BMO Capital Starts Energy Fuels (UUUU) at Outperform
- Goldman Sachs Reinstates Etsy (ETSY) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
